Asociación entre las principales coomorbilidades existentes en personas mayores de 50 años que consultan en las UBAS de Imsalud puente Barco Leones, comuneros y la libertad con hepatotoxicidad secundaria al tratamiento antituberculoso en Cúcuta durante los años 2014-2016.

Abstract

Tuberculosis is a living epidemic in our country, whose symptomatology is cough and expectoration for more than 15 days, it´s diagnosis can be made by BK sputum and culture. Antituberculosis treatment consists of ethambutol, rifampizine, isoniazid and pyrazinamide, the last three are listed as hepatotoxic, it can be manifested as the increase of 5 times of transaminases without symptomatology and the increase of 3 times of transaminases when the symptomatology is present, this indicates the suspension of pharmacological therapy. The initial phase comprises 2 months with H, R, Z and E, with daily unit dose and the continuation phase 4 months with H and R, with intermittent therapy of 3 doses per week on non-consecutive days. The study is cross-sectional, a population study of 78 people aged over 50 years with diagnosed comorbidities besides the diagnosis of tuberculosis. The dependent variable is the presence of hepatotoxicity and the independent are the main comorbidities in the adult older than 50 years, hepatotoxicity is present with a prevalence of 0.13 of the cases studied, the comorbidity which is most associated is HIV with OR: 1,8, where tuberculosis and antituberculosis treatment do not cause hepatotoxicity unless this over-aggregated comorbidity is followed by Dyslipidemias, COPD and Type 2 Diabetes Mellitus. It should be noted that one of the most significant studies in the area, "Kim, Et al, 2013 "shows that people older than 50 years with comorbidities tended to have hepatotoxicity more frequently than those who did not (14% vs. 7%, p = 0.09)", (...) The older adult presents more cases hepatotoxicity secondary to antituberculosis treatment .